http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2004512511-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-10 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-56 |
| filingDate | 2001-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2004-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2004512511-A |
| titleOfInvention | Reagents and kits for comprehensive clotting and hemostasis determination |
| abstract | Disclosed are reagents and kits for determining whether a patient is hypercoagulable, hypocoagulable or normal. The test includes providing a test sample obtained from a patient and initiating clotting in the sample in the presence of an activator, wherein the activator is an endogenous tenase. It is added to the sample in an amount that produces dependent fibrin. Thereafter, the formation of endogenous tenase-dependent fibrin polymerization is monitored over time to elicit a time-dependent profile, and the results of monitoring fibrin polymerization are used to determine whether the patient is hypercoagulable, normal or hypocoagulable. Is determined. The coagulation activator is added in an amount that triggers a thrombin surge that depends on the propagation phase and the amplification pathway. In this way, the hemostatic ability of the sample can be evaluated in a single assay. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022145477-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021021737-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7091413-B2 |
| priorityDate | 2000-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 135.